Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2012

View Archived Issues

Phase III trials of human fibrinogen to commence in China

Ambit Biosciences reports novel JAK modulators

CalciMedica scientists disclose new CRAC blockers

Scientists in U.S. design new candidate immunotherapies

Concert Pharmaceuticals presents novel deuterated inhibitors of sPLA2

New anti-infective dendrimeric peptides discovered at U.S. university

Novel HCV NS5A inhibitor shows proof of concept in nonhuman primates

Destiny Pharma clear to begin clinical study of anti-staphylococcal drug in U.S.

Novel 2-spiro-proline derivative inhibits 11-beta-HSD1

Beneficial effects seen with ETC-1002 in patients with hypercholesterolemia

New diacylglycerol O-acyltransferase 1 inhibitors show promise to treat metabolic diseases

Research collaboration set for blood test for Alzheimer's disease risk

Joint venture launched for biosimilar development

Bayer HealthCare and Tsinghua University extend drug discovery partnership

German study links new gene to atherosclerosis

FDA issues first-of-a-kind guidance on premarket review of medical devices

Acadia Pharmaceuticals receives grant from Michael J. Fox Foundation

FDA responds to SPA for phase III elagolix trial

Nymox reports new data from follow-up study of NX-1207

BD and FIND join to improve availability of TB diagnostics in India

Affymax and Takeda receive first approval for Omontys

Morphotek completes enrollment in farletuzumab study

Janssen Pharmaceutica discovers new potential analgesics

Targacept reports topline results from two TC-6987 studies

GSK patents new RAR-related orphan receptor-gamma modulators

Medicago and Mitsubishi Tanabe Pharma form strategic alliance

Lee's Pharmaceutical licenses RegeneRx candidates in China, Hong Kong and Macau

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...